Nektar Therapeutics’ (NKTR) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report report published on Thursday morning,Benzinga reports. They currently have a $6.50 target price on the biopharmaceutical company’s stock. A number of other research analysts have also commented on the company. William Blair reiterated a “market perform” […]
HC Wainwright reaffirmed their buy rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report report published on Thursday morning,Benzinga reports. They currently have a $6.50 target price on the biopharmaceutical company’s stock. A number of other research analysts have also commented on the company. William Blair reiterated a “market perform” […]
